Ligand ID: EUI Drugbank ID: DB05239 (Cobimetinib) Indication: For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.